ZUG | Jotup

Annual Survey Results Highlight Industry-Leading Customer Satisfaction Ratings for Altoo Wealth Platform

Retrieved on:

Thursday, May 9, 2024

ZUG, Switzerland, May 9, 2024 /PRNewswire/ -- Altoo AG, a fintech that empowers investment professionals, family offices and individual ultra-high-net-worth clients to conveniently oversee their wealth, has announced the results of its annual client satisfaction survey. The data, which is focused on Altoo Wealth Platform usage, features, functionality and overall customer satisfaction scores, was gathered from a cross-section of Altoo customers.

Key Points:

Wealth management fintech shares client feedback scores on "world class asset management platform" benefits, performance, and customer service
ZUG, Switzerland, May 9, 2024 /PRNewswire/ -- Altoo AG, a fintech that empowers investment professionals, family offices and individual ultra-high-net-worth clients to conveniently oversee their wealth, has announced the results of its annual client satisfaction survey.
The data, which is focused on Altoo Wealth Platform usage, features, functionality and overall customer satisfaction scores, was gathered from a cross-section of Altoo customers.
While the survey results clearly show that Altoo's clients appreciate the platform and the technology behind it, they also demonstrate trust in the company's customer support capabilities, with an overwhelmingly positive, almost 100% customer satisfaction score.
For more information on the Altoo survey along with further statistics, read the companion survey article.

CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference

Retrieved on:

Thursday, May 9, 2024

CRSP, Webcast, Therapy, CRISPR Therapeutics, Bank, Conference

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m.

Key Points:

ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the Bank of America Securities Health Care Conference on Wednesday, May 15, 2024, at 12:20 p.m.
ET.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events .
A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Retrieved on:

Wednesday, May 8, 2024

Sickle cell disease, T1D, SHR, Cell, CRISPR, Partnership, CD19, CRISPR Therapeutics, Biomarker, Autoimmunity, SCD, LNP, Lupus, Kingdom, Porphobilinogen, ADC, Eye, ANGPTL3, RAAS, PBG, Therapy, Lymphoid leukemia, Vertex Pharmaceuticals, Type 1 diabetes, Pain, Cas9, AHP, Diabetes, Research, ALA, BP, CD70, AGT, Clinical trial, Government, G&A, TDT, Sale, CRSP, ALAS1, European, Disease, Patient, Liver, Gene, Society, Stem cell, Cardiovascular disease, SLE, Pharmaceutical industry

CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.

Key Points:

CASGEVY is the first therapy to emerge from a strategic partnership between CRISPR Therapeutics and Vertex Pharmaceuticals established in 2015.
CRISPR Therapeutics has two next-generation approaches with the potential to significantly expand the addressable population with SCD and TDT.
G&A Expenses: General and administrative expenses were $18.0 million for the first quarter of 2024, compared to $22.4 million for the first quarter of 2023.
Collaboration Expense: Collaboration expense, net, was $47.0 million for the first quarter of 2024, compared to $42.2 million for the first quarter of 2023.

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach

Retrieved on:

Wednesday, May 8, 2024

Pain, CRSP, Patient, SHR, Cas9, Cell, CRISPR, ALAS1, LNP, AHP, Gene editing, Angiotensin, Paratriathlon, RNA, IOP, ALA, Disease, Porphobilinogen, Liver, CRISPR Therapeutics, Gene, Eye, Society, Trabecular meshwork, MYOC, RAAS, Cardiovascular disease, BP, AGT, Biomarker, PBG, Therapy, Glaucoma

In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.

Key Points:

In addition, CRISPR Therapeutics announced the expansion of its in vivo pipeline with two new programs.
“The expansion of our in vivo pipeline speaks to the scalability of the platform and the exceptional translation capabilities of our team.
The addition of two more programs, CTX340 and CTX450, utilizing this LNP delivery technology demonstrates the modularity and scalability of the platform.
In today’s presentation, the Company presented data demonstrating efficient and specific delivery to TM cells in mouse, non-human primate, and ex vivo human eyes.

Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis

Retrieved on:

Wednesday, May 8, 2024

The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.

Key Points:

The Phase 2 ACUITY study is evaluating once-daily OCS-05 intravenous infusion in patients with AON.
OCS-05 has been granted orphan drug designation in both the United States and Europe, highlighting the importance of this unmet medical need.
In the meantime, we keep on working towards an IND submission for OCS-05 in the U.S. in 2024.
While corticosteroids are used to shorten the attack, there is no approved therapy for AON and unmet needs remain for therapies that can prevent vision loss after an acute episode of optic neuritis.

Oculis Reports Q1 2024 Financial Results and Provides Company Updates

Retrieved on:

Wednesday, May 8, 2024

The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.

Key Points:

The two ongoing Phase 3 52-week trials, DIAMOND-1 and DIAMOND-2, started as planned in December 2023 and February 2024, respectively.
Concurrently, the Company listed on the Nasdaq Iceland Main Market in addition to Nasdaq Global Market in the U.S.
Snehal Shah, Pharm.
The Company also aims to complete an IND submission for OCS-05 in the U.S. in 2024.
The Company’s management uses these measures to better analyze its financial results and better estimate its financial outlook.

MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update

Retrieved on:

Tuesday, May 7, 2024

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.

Key Points:

Dr. Jorge Santos da Silva, Chief Executive Officer of MoonLake Immunotherapeutics, said: “2024 is shaping up to be a strong year for MoonLake.
Research and development expenses for the quarter ended March 31, 2024, were $13.0 million, compared to $8.1 million in the previous quarter.
The increase was primarily due to expenses incurred to initiate the new clinical trials.
General and administrative expenses for the quarter ended March 31, 2024 were $6.8 million, similar to the $6.9 million incurred in the previous quarter.

Oculis to Present at Bank of America Global Healthcare Conference

Retrieved on:

Monday, May 6, 2024

OCS, Conference, Bank of America, Bank, Event, Encore

ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV.

Key Points:

ZUG, Switzerland, and BOSTON, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”) a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’ management will be attending and presenting at the Bank of America Healthcare Conference taking place on May 14-16, 2024 in Las Vegas, NV.
Riad Sherif, M.D., Chief Executive Officer of Oculis, will deliver a company presentation on Wednesday, May 15th at 11:20am PT at the Encore Hotel.
Interested investors should contact their Bank of America representative to request meetings.
A link to access company presentation, when available, will be posted to Oculis website on the Events & Presentation page under the Investors & Media section.

Unlock Financial Potential: EverestInvest Opens Doors To Global Markets

Retrieved on:

Thursday, May 2, 2024

CFD, Cryptocurrency, Environment, Contract for difference, Knowledge, Policy

ZUG, Switzerland, May 2, 2024 /PRNewswire-PRWeb/ -- The world of finance is a vast and ever-evolving landscape, brimming with opportunities for savvy investors. But for those who are just starting, navigating the complexities of the market can be daunting. This is where EverestInvest steps in, extending a welcoming hand and a secure platform to empower individuals of all experience levels to explore the fascinating realm of Contract for Difference (CFD) trading.

Key Points:

EverestInvest opens doors to global markets, offering a secure platform for individuals of all experience levels to explore CFD trading.
With over 100 financial assets available, advanced security measures, and comprehensive educational resources, EverestInvest aims to empower traders worldwide to confidently navigate the complexities of the financial landscape and achieve their goals.
"We envision EverestInvest as a gateway," explains Frank Morgan, a spokesperson for the company.
EverestInvest also broadens its horizon with a comprehensive suite of features and benefits to elevate the trading experience.

Powerledger and MYTILINEOS Collaborate for Clean Energy PPA Tracking and Smart Sourcing

Retrieved on:

Wednesday, April 17, 2024

GOS, RIC, AI, Kilowatt-hour, Blockchain, Power purchase agreement, Partnership, Professional, Carbon, EV, OTC Markets Group, MYTIL, ATH, Cryptocurrency

Powerledger partners with Greek energy and metals company, MYTILINEOS (through Protergia), to introduce, for the first time, one of its kind energy provenance tracking and tracing solutions in Greece.

Key Points:

Powerledger partners with Greek energy and metals company, MYTILINEOS (through Protergia), to introduce, for the first time, one of its kind energy provenance tracking and tracing solutions in Greece.
Zug, Switzerland--(Newsfile Corp. - April 17, 2024) - Powerledger in partnership with MYTILINEOS Energy & Metals (RIC: MYTr.AT) (ATH: MYTIL) (OTC Pink: MYTHY) (MYTILINEOS) through Protergia , introduces energy provenance tracking and tracing solutions in Greece.
Powerledger - MYTILINEOS partnership boasts several key features as following:
It allows consumers to trace, visualise near real-time energy using blockchain and AI.
"The Powerledger blockchain meticulously tracks and traces the supplied energy from its generation source to its point of consumption, from smart meter data.